title: Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
authors.forename: A
authors.initials: A
authors.lastname: Tchirkov
authors.forename: J-L
authors.initials: JL
authors.lastname: Couderc
authors.forename: B
authors.initials: B
authors.lastname: Périssel
authors.forename: C
authors.initials: C
authors.lastname: Goumy
authors.forename: A
authors.initials: A
authors.lastname: Regnier
authors.forename: N
authors.initials: N
authors.lastname: Uhrhammer
authors.forename: P
authors.initials: P
authors.lastname: Verrelle
authors.forename: M
authors.initials: M
authors.lastname: Berger
mesh_terms: D000328:Adult; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D014644:Genetic Variation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl